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WHIM syndrome is a rare immunodeﬁciency disorder that
is characterized by warts, hypogammaglobulinemia, infections,
and myelokathexis. While several gain-of-function mutations
that lead to C-terminal truncations, frame shifts and point
mutations in the chemokine receptor CXCR4 have been identiﬁed in WHIM syndrome patients, the functional effect of
these mutations are not fully understood. Here, we report on a
new WHIM syndrome mutation that results in a frame shift
within the codon for Ser339 (S339fs5) and compare the properties of S339fs5 with wild-type CXCR4 and a previously
identiﬁed WHIM syndrome mutant, R334X. The S339fs5 and
R334X mutants exhibited signiﬁcantly increased signaling
compared to wild-type CXCR4 including agonist-promoted
calcium ﬂux and extracellular-signal-regulated kinase activation. This increase is at least partially due to a signiﬁcant
decrease in agonist-promoted phosphorylation, β-arrestin
binding, and endocytosis of S339fs5 and R334X compared with
wild-type CXCR4. Interestingly, there were also signiﬁcant
differences in receptor degradation, with S339fs5 having a very
high basal level of degradation compared with that of R334X
and wild-type CXCR4. In contrast to wild-type CXCR4, both
R334X and S339fs5 were largely insensitive to CXCL12promoted degradation. Moreover, while basal and agonistpromoted degradation of wild-type CXCR4 was effectively
inhibited by the CXCR4 antagonist TE-14016, this had no effect on the degradation of the WHIM mutants. Taken together,
these studies identify a new WHIM syndrome mutant, CXCR4S339fs5, which promotes enhanced signaling, reduced phosphorylation, β-arrestin binding and endocytosis, and a very
high basal rate of degradation that is not protected by antagonist treatment.

WHIM syndrome is a rare, genetic disease, which is named
for its four key clinical manifestations, Warts, Hypogammaglobulinemia, recurrent Infections, and Myelokathexis (1).
WHIM syndrome mainly results from heterozygous gain-of* For correspondence: Jeffrey L. Benovic, jeffrey.benovic@jefferson.edu.

function mutations in the chemokine receptor CXCR4, a
352 amino acid G-protein-coupled receptor (GPCR) that
contains a Ser/Thr-rich C-terminal tail that is a primary region of regulation. CXCR4 is broadly expressed and has an
important role in the immune system (1–3). Previous studies
have identiﬁed a total of 11 autosomal dominant mutations in
CXCR4 across 105 patients that result in WHIM syndrome
with the most prevalent being a truncation after Lys333
(R334X) (1). R334X has been the most extensively characterized mutation and has been shown to have increased
agonist (CXCL12)-promoted signaling, increased G protein
interaction, reduced interaction with GPCR kinase 6 (GRK6)
and β-arrestin2, and impaired receptor internalization
(1, 4–7). An S338X mutation has also been extensively
studied and has many properties similar to R334X with
increased signaling and G protein interaction and decreased
β-arrestin2 binding and receptor internalization (8–12).
Another WHIM mutation that has been well studied is
E343K, which has increased signaling and reduced receptor
phosphorylation and internalization (13–15). Interestingly,
one WHIM syndrome patient has also been identiﬁed with a
defect in the protein kinase GRK3 resulting in increased
CXCL12-promoted signaling and impaired desensitization
and internalization (16, 17).
CXCR4 has been extensively investigated and implicated
in several diseases besides WHIM syndrome including acquired immunodeﬁciency syndrome (AIDS), where it serves
as a coreceptor for human immunodeﬁciency virus (HIV),
and cancer, where it has a role in metastasis (18, 19).
Moreover, CXCR4 mutations found in WHIM syndrome
also occur in 30% of the cases of the plasma cell cancer
Waldenstrom’s macroglobulinemia (20, 21). Recent cancer
genome deep sequencing efforts have also revealed a higher
frequency of mutations in CXCR4 in some tumor types,
such as diffuse large B-cell lymphoma, uterine corpus
endometrial carcinoma, and skin cutaneous melanoma (22).
The C-terminal mutations in CXCR4 that occur in WHIM
syndrome appear to disrupt the normal mechanisms
involved in regulating CXCR4 function, which include
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agonist-dependent phosphorylation of the receptor by GRKs
and protein kinase C (PKC), desensitization mediated by
β-arrestin binding, ubiquitination by the E3 ubiquitin ligase
AIP4, endocytosis, and sorting to lysosomes where the receptor is degraded (14, 23–26). CXCR4 has also been shown
to regulate several signaling pathways primarily via its
interaction with Gi although it can also activate G13 (18, 27).
While C-terminal truncations and mutations in CXCR4 have
been shown to enhance CXCR4 signaling and lead to
WHIM syndrome, we still have an incomplete picture of
how these changes alter CXCR4 function.
Here we focused on understanding the characteristics of a
new WHIM syndrome mutation in CXCR4 that we identiﬁed that contains a frame shift in the codon for Ser339
resulting in ﬁve additional residues (S339fs5). Patients that
have this mutation exhibit many characteristics of WHIM
syndrome including recurrent warts, human papillomavirusassociated cervical dysplasia, frequent respiratory tract infections, and leukopenia with bone marrow biopsy evidence
of myelokathexis. To better understand the characteristics of
S339fs5 that might contribute to its role in WHIM syndrome, we generated a stable cell line expressing S339fs5
and compared its properties with wild-type (WT) CXCR4
and with another WHIM syndrome mutant, R334X. S339fs5
and R334X have a defect in the normal mechanisms involved
in CXCR4 regulation including decreased agonist-promoted
phosphorylation, β-arrestin binding, and endocytosis ultimately leading to enhanced signaling compared to WT

CXCR4. S339fs5 also appears to have a higher basal rate of
degradation compared with R334X and WT CXCR4 suggesting that S339fs5 levels might be lower compared with
WT CXCR4 in these patients.

Results
Phenotypic characterization of a family with WHIM syndrome
Here we report on a new patient cohort containing a mutation in CXCR4 that results in a frame shift within the codon
for Ser339 (S339fs5) (Fig. 1). Data from the index case (P1)
show leukopenia with marked neutropenia and decreased
class-switched memory B cells with normal quantitative immunoglobulins. Infections, such as other CXCR4 WHIM
syndrome variants, include human papillomavirus-associated
disease including warts and mucosal intraepithelial lesions.
Nonepithelial infections in P1 and her father (P2) are restricted
to the respiratory tract. A comparison of the sequence of
S339fs5 with other reported WHIM syndrome mutations is
shown in Fig. S1.
Generation of stably overexpressing HEK293 cell lines
To characterize the properties of the new S339fs5 mutation,
we generated HEK293 cells stably overexpressing Flag-tagged
S339fs5 as well as a stable line overexpressing another
WHIM mutant R334X, the most prevalent mutation found in
WHIM syndrome patients. ELISA was then used to compare
the cell surface expression of S339fs5 and R334X with a line
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Figure 1. Characterization of a new WHIM syndrome cohort. A, pedigree of a family that has symptoms of WHIM syndrome. B, left panel—peripheral
smear of patient P1; right panel—bone marrow biopsy from patient P1 showing myelokathexis. C, sequence analysis of CXCR4 from patient P1 with the
altered base pair and amino acid sequences compared with wild-type CXCR4 shown in red. D, cell surface expression of WT CXCR4, S339fs5 (S339fs), and
R334X as measured by ELISA from 6 to 8 experiments with mean ± SD shown.
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that we had previously developed expressing WT CXCR4 (25).
This showed that S339fs5 and R334X were expressed at
75–85% of the level observed in WT CXCR4 expressing cells
(Fig. 1D).

Effects of WHIM mutations on CXCR4 signaling
Previous studies have noted that CXCR4 mutations involved
in WHIM syndrome have enhanced signaling. To compare the
signaling of S339fs5 with R334X and WT CXCR4, we initially
looked at the ability of the CXCR4 agonist CXCL12 to stimulate a calcium ﬂux. CXCL12 was found to promote a low level
of calcium ﬂux in untransfected HEK293 cells due to a low
level of endogenous CXCR4 (Fig. 2A). This response was
modestly increased in cells overexpressing WT CXCR4, a
ﬁnding that we previously observed in these cells (25). In
contrast, calcium ﬂux was increased several fold in cells
expressing R334X and almost tenfold in cells expressing
S339fs5. We also evaluated the ability of the Gi-biased CXCR4
pepducin ATI-2341 (28) to stimulate a calcium ﬂux in the
various lines. Untransfected HEK293 cells had a low level of
calcium ﬂux, cells expressing WT CXCR4 had a much higher
level of response to ATI-2341, R334X cells were comparable to
WT, and S339fs5 cells were increased approximately threefold
compared with WT CXCR4 (Fig. 2B). Overall, these studies
show that both S339fs5 and R334X have enhanced calcium
signaling compared with WT CXCR4 with S339fs5 being the
most responsive.
CXCR4 also promotes the phosphorylation of extracellularsignal-regulated kinase (ERK)1/2 through Gi and GRK/βarrestin-dependent pathways (25, 28). Our results show low
ERK1/2 activation induced by CXCL12 in untransfected
HEK293 cells with a signiﬁcant increase in cells expressing
WT CXCR4 as previously demonstrated (25 and data not
shown). Cell lines expressing R334X or S339fs5 had enhanced

A

CXCL12-promoted ERK1/2 activation compared with WT
CXCR4 cells with R334X being the most responsive (Fig. 3,
A and B). Similarly, ERK1/2 activation induced by ATI-2341
showed some activation in untransfected HEK293 cells with
an increase in cells expressing WT CXCR4 (data not shown).
The cell lines expressing R334X or S339fs5 both had enhanced
ATI-2341-promoted ERK1/2 activation compared with WT
CXCR4 with R334X again being the most active (Fig. 3, C and
D). Taken together, these studies show that both S339fs5 and
R334X have enhanced ERK1/2 activation compared with WT
CXCR4 with R334X being the most responsive.

Effects of WHIM mutations on CXCR4 phosphorylation
Increased signaling suggests increased activation of Gidependent pathways possibly due to a decrease in the
mechanisms that desensitize or turn-off CXCR4 activation of
Gi. Previous studies support a role for GRK and PKCmediated phosphorylation of CXCR4 in the desensitization
process (25). In particular, CXCL12-mediated phosphorylation of far C-terminal residues such as Ser346-8 by GRK2/3 is
thought to promote β-arrestin binding, which functions in
the desensitization process (14, 25, 26). While these residues
are not present in R334X or S339fs5, Ser324 and Ser325
(S324/5) are present and also contribute to the desensitization process as well as to CXCR4 endocytosis and degradation (23). Thus, we next evaluated CXCL12 and ATI-2341mediated phosphorylation of S324/5 using phospho-speciﬁc
antibodies that we previously generated and validated (25).
While CXCL12 and ATI-2341 induced rapid and robust
phosphorylation of S324/5 in WT CXCR4, there was a lower
basal level of phosphorylation and minimal agonist-induced
phosphorylation of S339fs5 and R334X (Fig. 4, A and B). It
is also worth noting that we see reduced mobility of WT
CXCR4 following agonist treatment due to phosphorylation

B

Figure 2. Analysis of calcium ﬂux in HEK293 cells with or without stable expression of WT CXCR4 or WHIM mutants S339fs5 and R334X. HEK293
cells grown in a 96 well plate were loaded with Fluo4-AM at 37  C for 1 h and washed with Hank’s buffer. Cells were stimulated with 50 nM CXCL12 (A) or
3 μM ATI-2341 (B), a Gi-biased pepducin for CXCR4, and the ﬂuorescence intensity was monitored over 120 s. These results are representative of four
experiments.
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Figure 3. Analysis of ERK1/2 activation in HEK293 cells stably expressing WT CXCR4 or WHIM mutants S339fs5 and R334X. HEK293 cells were
incubated in serum-free medium for 4 h and then stimulated with 50 nM CXCL12 (A and B) or 3 μM ATI-2341 (C and D). Panels A and C show a representative time course of ERK1/2 phosphorylation while panels B and D summarize results from six individual experiments as fold over basal with mean ± SD
shown. p < 0.05 at 3 min, p < 0.01 at 10 min and p = 0.05 at 30 min when comparing S339fs5 with WT stimulated with CXCL12. p < 0.05 at 3, 10, and 30 min
when comparing R334X with WT stimulated with CXCL12.

A

B

Figure 4. Analysis of CXCR4 phosphorylation at serines 324 and 325 (pS324/5) in HEK293 cells stably expressing WT CXCR4 or WHIM mutants
S339fs5 and R334X. HEK293 cells were starved in serum-free medium for 4 h and then stimulated with 50 nM CXCL12 or 3 μM ATI-2341. A, representative Western blot of CXCR4 detected using a pS324/5 speciﬁc antibody or Flag antibody. B, data summarizing the quantiﬁcation of CXCR4-pS324/5
from four individual experiments in cells expressing WT CXCR4, CXCR4-S339fs5, or CXCR4-R334X with mean ± SD shown. p < 0.001 at basal, 3 min and
10 min, and p < 0.05 at 30 min when comparing S339fs5 with WT stimulated with CXCL12. p < 0.005 at basal and 10 min, p < 0.001 at 3 min, and
p < 0.05 at 30 min when comparing R334X with WT stimulated with CXCL12. p < 0.001 at basal, p < 0.005 at 3 min, and p < 0.05 at 10 and 30 min when
comparing S339fs5 with WT stimulated with ATI-2341. p < 0.01 at basal, 3 and 10 min, and p < 0.05 at 30 min when comparing R334X with WT
stimulated with ATI-2341.
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of the receptor as previously shown (25), while no mobility
shift was observed with the WHIM mutants (Fig. 4A). Thus,
S339fs5 and R334X undergo minimal agonist-promoted
phosphorylation of critical residues involved in regulating
CXCR4 function.
Effects of WHIM mutations on β-arrestin binding
Previous studies have shown that β-arrestins bind to CXCR4
in an agonist- and phosphorylation-dependent manner and
play an important role in regulating CXCR4-mediated
signaling (16, 18, 25, 26). To evaluate whether the WHIM
mutants have a defect in β-arrestin binding, we utilized a
bioluminescence resonance energy transfer (BRET) assay to
study the translocation of β-arrestin2 from the cytoplasm to
the plasma membrane upon receptor activation (29). Initial
studies to validate the assay demonstrated CXCL12-dependent
translocation of β-arrestin2 in HEK293 cells expressing WT
CXCR4 with no translocation in untransfected cells (Fig. 5A).
We also did not detect signiﬁcant translocation of β-arrestin2
in either the S339fs5- or R334X-expressing cells (Fig. 5A).
Thus, the S339fs5 and R334X WHIM mutants have a defect in
β-arrestin binding most likely due to the truncated C-terminus
and reduced C-terminal phosphorylation compared with WT
CXCR4.
Effects of WHIM mutations on CXCR4 endocytosis
One important aspect of CXCR4 regulation is agonistpromoted endocytosis, which ultimately is critical in the subsequent sorting and degradation of the receptor. While the
mechanism of this endocytosis has not been fully dissected, it
has been shown that PKC activation can induce CXCR4
endocytosis via a pathway that is likely β-arrestin independent
(30). WT CXCR4 was found to undergo rapid CXCL12induced endocytosis achieving 35% after 1 h of agonist

treatment (Fig. 5B). CXCL12-induced endocytosis of R334X
was signiﬁcantly reduced with a maximum of 15% at 1 h
while S339fs5 was reduced even further with a maximum of
10% (Fig. 5B). Since the phosphorylation of S324/5 plays an
important role in the endocytic process (23), it is not surprising that agonist-dependent endocytosis of S339fs5 and
R334X is signiﬁcantly ablated given the low level of pS324/5
that was observed (Fig. 4).
Effects of WHIM mutations on basal and agonist-promoted
degradation of CXCR4
CXCR4 is also regulated by sorting to lysosomes where it is
degraded (23, 24). To evaluate potential differences in the
degradation of WT, S339fs5, and R334X CXCR4, we ﬁrst
treated the overexpressing cells with cycloheximide for 10 min
to inhibit new protein synthesis. We then treated the cells with
buffer, CXCL12 or ATI-2341 for 0 to 6 h and assessed CXCR4
levels by immunoblotting. WT CXCR4 undergoes signiﬁcant
basal degradation in this system with a half-life of 4-h while
CXCL12 signiﬁcantly increased the rate of degradation with a
half-life of 1.4 h (Fig. 6, A and B). ATI-2341 also enhanced
the rate of CXCR4 degradation although it was not as significant as observed with CXCL12 (Fig. 6, C and D). While R334X
had a basal rate of degradation similar to WT CXCR4, there
was no signiﬁcant effect of CXCL12 or ATI-2341 treatment
(Fig. 6). Interestingly, S339fs5 had a higher basal rate of
degradation with a half-life of 2.5 h but, similar to R334X, it
was largely insensitive to agonist treatment (Fig. 6). Thus, the
rates of degradation of WT, R334X, and S339fs5 are signiﬁcantly different with WT being sensitive to agonist treatment,
R334X and S339fs5 being agonist-insensitive, and S339fs5
having a higher basal rate of degradation.
To try to better understand potential mechanistic differences between the degradation of WT CXCR4 and the WHIM

Figure 5. Analysis of β-arrestin2 translocation and CXCR4 internalization in HEK293 cells expressing WT CXCR4 or WHIM mutants S339fs5 and
R334X. A, HEK293 cells were transiently transfected with Rluc8-β-arrestin2-Sp1 and M-L-citrine-SH3 with or without WT CXCR4, S339fs5, or R334X and
analyzed for CXCL12-dependent BRET 48 h after transfection. The data are from ﬁve experiments with mean ± SD shown. B, HEK293 cells stably expressing
WT CXCR4 or WHIM mutants S339fs5 and R334X grown in a 24-well plate were treated with 50 nM CXCL12 at 37  C for 0 to 60 min and the cells were ﬁxed,
incubated with anti-ﬂag polyclonal antibody, and cell surface receptors detected by chemiluminescence as described in Experimental procedures. The data
from at least six individual experiments with mean ± SD shown (*p < 0.05; **p < 0.001).
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Figure 6. Analysis of CXCR4 degradation in HEK293 cells stably expressing WT CXCR4 or WHIM mutants S339fs5 and R334X. Cells grown in a 12 well
plate were pre-incubated with 20 μg/ml of cycloheximide (CH) for 10 min and then incubated with or without 50 nM CXCL12 (A and B) or 3 μM ATI-2341
(C and D) for 0 to 6 h. Receptor degradation was analyzed by Western blot using an anti-ﬂag polyclonal antibody. A and C, representative Western blot of
CXCR4 after treatment with CXCL12 or ATI-2341 for 0 to 6 h. B and D, quantiﬁcation of CXCR4 degradation from eight individual experiments was analyzed
using a LI-COR scanner with mean ± SD shown: p < 0.01 at 1 and 6 h, and p < 0.05 at 3 h when comparing basal WT degradation with CXCL12 stimulated
degradation; p < 0.01 at 6 h when comparing S339fs5 with WT basal degradation. p < 0.01 at 1 and 3 h, and p < 0.05 at 6 h when comparing basal WT
degradation with ATI-2341 stimulated degradation.

mutants, we treated cells with the high afﬁnity CXCR4
antagonist TE14016 or the PKC inhibitor Bis I. TE14016
signiﬁcantly inhibited basal degradation as well as CXCL12promoted degradation of WT CXCR4 while Bis I partially
inhibited basal degradation (Fig. 7, A and B). In contrast, we
did not see a signiﬁcant effect of TE14016 or Bis I treatment
on the degradation of S339fs5 (Fig. 7, C and D) or R334X
(Fig. 7, E and F). Thus, the higher basal rate of degradation of
S339fs5 does not appear to be due to PKC-mediated phosphorylation of the receptor.

Discussion
In the present study, we report on a new patient cohort
containing a mutation in CXCR4 that results in a frame shift
within the codon for Ser339 resulting in the addition of ﬁve
new residues after Ser338 (CXCR4-S339fs5). To better understand the properties of S339fs5 compared with WT CXCR4
and other WHIM syndrome mutants such as R334X, we
established HEK293 cell lines stably expressing WT or mutant
CXCR4. S339fs5 had enhanced agonist-promoted signaling,
decreased phosphorylation, decreased β-arrestin binding,
decreased endocytosis, and an increased rate of basal degradation compared with WT CXCR4. Previous studies reported
on a group of six patients that have a different frame shift in
CXCR4 within the codon for Ser339 (S339fs3), although this
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mutation was never characterized. S339fs3 would likely have
characteristics similar to the S339fs5 mutation that we identiﬁed in the current work, although it is possible that the
residues after Ser338 might lead to additional changes in
CXCR4 function. Nevertheless, we would anticipate that all
patients that have a frame shift within the Ser339 codon would
have signiﬁcantly enhanced signaling, reduced receptor phosphorylation, β-arrestin binding, and endocytosis, and an
increased rate of basal degradation that is not altered by
CXCR4 antagonists. We speculate that treating these patients
with a CXCR4 antagonist could reduce the high level of
signaling and help to normalize CXCR4 function.
Previous studies have extensively characterized the mechanisms involved in the regulation of CXCR4. CXCR4 is rapidly
phosphorylated following activation by CXCL12 with primary
sites being Ser324/5, Ser330, Ser339, and Ser346/7 (14, 24, 25).
The primary kinases that mediate phosphorylation of these
sites include GRK6 and PKC for Ser324/5, GRK6 for Ser330
and Ser339, and GRK2 and/or GRK3 for Ser346/7 (14, 25, 26).
Functional effects of CXCR4 phosphorylation include
enhanced β-arrestin binding and desensitization (25, 26),
ubiquitination of C-terminal arginines by the E3 ligase AIP4
(24), and endocytosis and sorting of the receptor for degradation (23, 24). Some of these processes have been linked with
speciﬁc sites of phosphorylation although mechanistic details
of this are incomplete. For example, mutation of Ser324/5 to
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Figure 7. Effects of a CXCR4 antagonist and PKC inhibitor on CXCR4 degradation in HEK293 cells stably expressing WT CXCR4 or WHIM mutants
S339fs5 and R334X. A time course of CXCL12-promoted CXCR4 degradation in the presence or absence of 1 μM of the CXCR4 antagonist TE14016 or
10 μM of the PKC inhibitor Bis I was performed. Panels A, C, and E show representative Western blots of basal and CXCL12-induced CXCR4 degradation in
the presence or absence of TE14016 or Bis I. Panels B, D, and F show quantiﬁcation of CXCR4 degradation from at least six individual experiments with
mean ± SD shown. WT: p < 0.01 at 1, 3, and 6 h when comparing basal degradation with CXCL12 stimulated degradation; p < 0.01 at 1 h when comparing
TE14016 on basal degradation; p < 0.01 at 1, 3, and 6 h when comparing TE14016 on CXCL12 stimulated degradation; Bis I has no effect on basal
degradation. S339fs5: p < 0.01 at 3 and 6 h when comparing basal degradation with CXCL12 stimulated degradation. R334X: p < 0.05 at 3 and 6 h when
comparing TE14016 on basal degradation; p < 0.05 at three and p < 0.01 at 6 h when comparing TE14016 on CXCL12 stimulated degradation; Bis I has no
effect on basal or CXCL12 stimulated degradation.

alanine results in a complete loss of agonist-promoted degradation and signiﬁcant decrease in endocytosis of CXCR4 while
S330A mutation results in an 50% reduction in degradation
and no effect on endocytosis (23). Interestingly, recent studies
have also shown that the phosphorylation of far C-terminal
residues such as Ser346/7 appears to be critical in the phosphorylation of additional residues including Ser324/5, Ser338/
9, and possibly Ser330 (14, 31). This may be due to reduced
binding of COMMD3/8 leading to a loss of GRK6 recruitment
and reduced phosphorylation of residues that contribute to
endocytosis, ubiquitination, and lysosomal degradation (31).
While we have not evaluated COMMD3/8 binding, we do see
a signiﬁcant reduction in agonist-promoted phosphorylation
of Ser324/5 in S339fs5 and R334X suggesting a reduced ability
of GRK6 to phosphorylate these sites (Fig. 4).
Previous studies have also extensively characterized the
properties of a few other WHIM syndrome mutants. R334X
has increased CXCL12-promoted signaling and increased
interaction with G protein (4, 6, 7) as well as a defect in GRK6
and β-arrestin2 binding causing delayed receptor internalization and desensitization (5), although these studies did not
evaluate effects on receptor phosphorylation. Our work shows
reduced agonist-promoted phosphorylation and degradation
of R334X. CXCR4-S338X has increased signaling and G protein interaction and decreased β-arrestin2 binding and receptor internalization (8–12) so it appears similar to R334X.

Interestingly, a gain-of-function E343K mutation in CXCR4
was initially reported in a patient cohort by Liu et al. (13).
E343K was shown to be defective in agonist-promoted phosphorylation of multiple C-terminal sites including S324/5,
S338/9, and S346/7 (14). This mutation was further characterized by Wang et al. (15), who found that having an acidic
residue at position 343 was essential in maintaining normal
function and that mutation to Arg, Lys, or Ala enhanced
agonist-promoted signaling and impaired desensitization of
CXCR4. While the mechanism of reduced phosphorylation
was not determined, the mutation likely results in reduced
phosphorylation of C-terminal serines that are normally
phosphorylated by GRK2 and/or GRK3 (14, 25, 26) since these
kinases preferentially phosphorylate Ser/Thr in an acidotropic
environment (32).
Taken together, our studies provide insight on a new mutation in CXCR4 that results in WHIM syndrome and help to
deﬁne the mechanisms involved in the altered regulation of
WHIM mutants including S339fs5 and R334X.

Experimental procedures
Materials
HEK293 cells were obtained from Microbix Biosystems, Inc,
while Lipofectamine 2000 and Opti-MEM were from Invitrogen. Anti-CXCR4 monoclonal antibodies were obtained
J. Biol. Chem. (2022) 298(2) 101551
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from BD Biosciences Pharmingen. Anti-CXCR4 phosphoserine 324/5 (pS324/5) antibodies were previously described
(25). Anti-ﬂag-tagged monoclonal and polyclonal antibodies
and anti-α-tubulin monoclonal antibodies were obtained from
Sigma-Aldrich. The CXCR4 pepducin ATI-2341 was synthesized by Peptide 2.0 Inc.
Patient information
The index patient (P1) is a 41-year-old female who was
found to have leukopenia at birth. Since there was no obvious
illness associated with the ﬁnding, no further investigation was
undertaken at that time. Sinus and ear infections began in
grade school and warts were ﬁrst noted at 12 years of age. At
17 years of age, she was found to have a low white blood cell
(WBC) count of 1.4 × 103 and was referred to the local children’s hospital for evaluation. No etiology for the leukopenia
was identiﬁed. At 17, she had sinus surgery due to recurrent
sinus infections. At 26 years of age, she was found to be hypothyroid. At 28 years of age, a bone marrow biopsy was obtained. Myelokathexis was appreciated but no additional
diagnosis was made. She was found to have HPV with cervical
intraepithelial neoplasia 1 requiring a loop electrosurgical
excision procedure. The patient continues to experience
recurrent episodes of sinusitis and 2–3 episodes of bronchitis
yearly. P1’s father (P2) was found to have neutropenia as a
child. Since the family lived on a farm, the low WBC count was
attributed to chemical exposure. He had a history of multiple
pneumonias, warts, and hypothyroidism. He received multiple
doses of granulocyte colony stimulating factor (G-CSF), which
were effective at increasing WBC counts. His death at 56 years
of age was attributed to a pulmonary embolism. P1 has two
half siblings (P3, P4). P3 is a male with a history of neutropenia
and extensive hand warts. P4 is a male with neutropenia, warts,
and MRSA positive skin infections. Therapy with G-CSF has
been effective at increasing WBC counts in P4. P1’s paternal
grandfather had polycythemia requiring frequent phlebotomies. P1 has a 15-month-old daughter (P5) who is neutropenic
but asymptomatic. CXCR4 sequencing of P1 and P5 has
identiﬁed the S339fs5 variant. This work was evaluated by the
Ann & Robert Lurie Children’s Hospital of Chicago IRB and
found to be exempt (IRB #2021-4860).
Cell culture and generation of stable cell lines
Flag-tagged human CXCR4 was previously described (24)
and was used to generate plasmids for the WHIM mutations
S339fs5 and R334X using the following primers: S339fs5:
Forward: 50 -TTTCCACTAATCTAGAGGGCCCTATTC-3’;
Reverse: 50 - CAGATGAATGAA TGTCCACCTCGCTT-3’.
R334X: Forward: 50 -CAAAGGAAAGTGAGAGGTGGACA
TTC-3’;
Reverse:
50 -GAGAGGATCTTGAGGCTG-3’.
HEK293 cells were maintained in Dulbecco’s modiﬁed Eagle’s
medium (DMEM) supplemented with 10% fetal bovine serum
(FBS), 25 mM HEPES, pH 7.2, and 0.1 mM nonessential
amino acids (complete media) in a 5% CO2 humidiﬁed
incubator at 37  C. HEK293 cells stably expressing WT
CXCR4 were previously described (25) while cell lines
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expressing S339fs5 and R334X were transfected with the
appropriate plasmid and selected and maintained in complete
media supplemented with 0.8 mg/ml G418 and penicillin/
streptomycin.
Detection of CXCR4 phosphorylation
Cells were plated into 12-well plates and cultured for 24 h.
Cells were starved with serum-free DMEM for 4 h prior to
stimulation with agonist. Cells were then washed twice with
ice-cold phosphate buffered saline (PBS) and lysed with buffer
containing 20 mM HEPES, pH 7.2, 10 mM EDTA, 150 mM
NaCl, 1% Triton X-100, and one tablet each of minicomplete
protease inhibitor and PhosSTOP phosphatase inhibitor
(Roche) per 10 ml at 4  C on a rocker for 30 min. The lysates
were cleared by centrifugation at 14,000 rpm in an Eppendorf
centrifuge for 20 min at 4  C. Total protein in cell lysates was
measured using the Bio-Rad Protein Assay. An equal amount
of total protein was electrophoresed on a 10% SDS polyacrylamide gel, transferred to nitrocellulose, and immunoblotted with the following primary antibodies: polyclonal antipS324/5-CXCR4 (1:1000) and either monoclonal anti-CXCR4
(1:1000) or polyclonal anti-ﬂag (1:2000). Blots were washed
extensively with Tris-buffered saline (TBS) plus 0.02% Tween
20 (TBST), incubated with a horseradish peroxidase–labeled
secondary antibody, washed with TBST, and then proteins
were detected using chemiluminescence. The blots were
stripped and reprobed using an antitubulin monoclonal antibody. Western blots were visualized and quantiﬁed using a
C-DiGit Blot Scanner and Image Studio Software (LI-COR).
ERK activation assays
HEK293 cells expressing Flag-tagged WT or mutant CXCR4
at 90% conﬂuence in 12-well plates were serum starved for
4 h and then stimulated with either 50 nM CXCL12 or 3 μM
ATI-2341 and washed once with ice cold PBS. Lysis buffer
(1% Triton X-100, 20 mM HEPES, pH 7.2, 150 mM NaCl,
10 mM EDTA, phosphatase inhibitor, and protease inhibitor)
was added on ice, the cells were rocked at 4  C for 30 min, and
debris was cleared by centrifugation at 14,000 rpm for 20 min.
Equal amounts of whole cell lysate were separated by electrophoresis on a 10% SDS polyacrylamide gel, transferred to
nitrocellulose, and proteins were detected by immunoblotting.
Nitrocellulose membranes were blocked for 1 h at room
temperature in a 1:3 dilution of ODYSSEY blocking buffer (LICor Biosciences) and a mixture of primary antibodies directed
at ERK2 (monoclonal, Santa Cruz) and phospho-ERK1/2
(polyclonal, Cell Signaling Technologies) in 100% ODYSSEY
blocking buffer were incubated with the nitrocellulose overnight at 4  C. Nitrocellulose membranes were washed three
times for 15 min with TBST. The membranes were then
incubated for 1 h at room temperature with a mixture of goat
anti-rabbit Alexa Fluorophore 680 conjugated (LI-Cor Biosciences) and goat anti-mouse IRDye 800 conjugated (LI-Cor
Biosciences) antibodies. Following a 1 h incubation, the
membranes were washed with TBST three times for 20 min
each. Fluorescence was detected simultaneously using the
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ODYSSEY infrared imaging system (LI-Cor Biosciences).
Fluorescence intensity of phosphorylated ERK1/2 was
normalized to total ERK2 ﬂuorescence, and data are represented as fold-increase over basal ± SEM.
Measurement of intracellular calcium mobilization
HEK293 cells stably expressing CXCR4 were plated at
20,000 to 25,000 cells/well in 100 μl of media into poly-l-lysine
(Sigma) coated 96-well plates and incubated at 37  C overnight. Medium was aspirated and cells were loaded with
2.5 μM Fluo-4 AM in 50 μl Hanks buffered saline solution
(HBSS) containing 10 mM HEPES, pH 7.2, and 0.25% pluronic
(Life Tech). Plates were incubated at room temperature for 1 h
in the dark, the dye was aspirated, and the plate was washed
with HBSS one time. Cells were stimulated with 50 nM
CXCL12 or 3 μM ATI-2341 in 100 μl HBSS, and the calcium
ﬂux was monitored with Clariostar Plus (BMG Labtech), a
multimode microplate time-resolved ﬂuorescence reader.
Analysis of β-arrestin translocation using BRET
We used a β-arrestin translocation assay to monitor the
movement of a BRET donor-tagged β-arrestin2 from the
cytoplasm to the plasma membrane upon GPCR activation as
previously described (29). Brieﬂy, 100,000 HEK293 cells/well
in a 96-well opaque microplate (PerkinElmer) were transiently
cotransfected with the BRET biosensors Rluc8-β-arrestin2-SP1
(25 ng/well) and M-L-Citrine-SH3 (500 ng/well) with or
without 20 ng/well of Flag-CXCR4, Flag-CXCR4-S339fs5, or
Flag-CXCR4-R334X using Metafectene Pro (Biontex). Fortyeight hours after transfection, cells were stimulated with
increasing concentrations of CXCL12 (ProSpec) in the presence of 5 μM Renilla luciferase coelenterazine H (Cayman
Chemical Company) for 20 min. Signals were recorded with a
Tecan Inﬁnite F500 plate reader.
Analysis of cell surface expression and internalization of
CXCR4
Cell surface expression of Flag-tagged WT and mutant
CXCR4 was measured by ELISA as previously described (33).
Brieﬂy, HEK293 cells stably expressing Flag-tagged CXCR4
were split into 24-well plates coated with poly-l-lysine. The
following day, the medium was aspirated and cells were ﬁxed
for 10 min at room temperature with 3.7% formaldehyde in
TBS. Cells were washed three times with TBS and then
blocked for 45 min with 1% bovine serum albumin in TBS.
Cells were then incubated for 1 h with a rabbit polyclonal Flag
antibody diluted 1:1000, washed three times, blocked for
15 min, and incubated for 1 h with goat anti-rabbit alkaline
phosphatase-conjugated antibody (Vector) diluted 1:1000.
Cells were washed two times, and antibody binding was
measured by adding 0.25 ml ABTS (Fisher) to each well and
incubating at room temperature for 25 min. Plates were read at
405 nm in a microplate reader (Bio-Rad) using Microplate
Manager software.
To evaluate agonist-promoted internalization of WT and
mutant CXCR4, HEK293 cells stably expressing Flag-tagged

CXCR4 in 24-well plates were washed with serum-free
DMEM and then stimulated with 50 nM CXCL12 for 0 to
60 min. The medium was aspirated, cells were ﬁxed, and cell
surface expression was analyzed using a rabbit Flag antibody
and goat anti-rabbit alkaline phosphatase-conjugated antibody
as described above.
Analysis of CXCR4 degradation
To measure CXCR4 degradation, we followed a previously
described protocol (23). Brieﬂy, HEK293 cells expressing stably
transfected WT or mutant CXCR4 were initially incubated in
DMEM media with 10% FBS containing 10 μg/ml cycloheximide for 10 min at 37  C. Cells were then incubated in the
same media at 37  C with or without 50 nM CXCL12 for 0, 1,
3, or 6 h. Cells were lysed by addition of lysis buffer on ice and
rocked at 4  C for 30 min, debris was cleared by centrifugation
at 14,000 rpm for 20 min, and proteins were resolved by SDSPAGE and transblotted onto nitrocellulose. Blots were incubated with an anti-Flag polyclonal antibody and analyzed by
chemiluminescence. Blots were then stripped and probed using an anti-α-tubulin primary antibody (Sigma). Films were
quantiﬁed using a LI-COR scanner and normalized for total
protein using the α-tubulin blot.
Statistics
Western blots were quantiﬁed on a LI-COR C-DiGit scanner. Data are shown as the mean ± SD with p values determined by comparing the data from experimental versus
control from at least three independent experiments using a
one-tailed t test in Excel. Where noted, n equals the number of
independent experiments that were performed.

Data availability
All data are contained within the manuscript. Additional
information and reagent requests should be directed to the
corresponding author.
Supporting information—This
information.
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